过去一年中添加的文章，按日期排序
Peptostreptococcus stomatis promotes colonic tumorigenesis and receptor tyrosine kinase inhibitor resistance by activating ERBB2-MAPK
P Huang, F Ji, AHK Cheung, K Fu, Q Zhou, X Ding… - Cell Host & Microbe, 2024 - cell.com
10 天前 - … MEK-ERK activation and abolished the efficacy of EGFR inhibitor, cetuximab, in
KRAS-wild-type CRC while also promoting non-response to vemurafenib in BRAFV600Emutant …
KRAS-wild-type CRC while also promoting non-response to vemurafenib in BRAFV600Emutant …
Understanding endogenous oncogenic KRAS mutations in isogenic near-diploid human cell lines derived from hTERT RPE-1
NL Hindul - 2024 - figshare.le.ac.uk
19 天前 - … Notably, KRASG12X/+ cells showed varying responses to different inhibitors, with
… and MEK inhibitors (U0126 and trametinib) but more resistant to the PI3K inhibitor PIK-90 …
… and MEK inhibitors (U0126 and trametinib) but more resistant to the PI3K inhibitor PIK-90 …
Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
H Kotani, H Oshima, JC Boucher, T Yamano… - Journal of Biomedical …, 2024 - Springer
24 天前 - … critical roles in KRAS-mutant cancer [23]. As expected, KRAS-mutant cancer cell
lines … to a commercially available MEK inhibitor, trametinib, than were KRAS wild-type cancer …
lines … to a commercially available MEK inhibitor, trametinib, than were KRAS wild-type cancer …
Reporter-based screening identifies RAS-RAF mutations as drivers of resistance to active-state RAS inhibition in colorectal cancer
O Aust, E Blanc, M Lüthen, V Hollek… - bioRxiv, 2024 - biorxiv.org
31 天前 - … KRAS mutations, as found in clinical studies(14, 15) as well as in in-vitro
experiments(14–16), mutations … In both SW480 and HT29 CRC cells, the MEK inhibitor decreased …
experiments(14–16), mutations … In both SW480 and HT29 CRC cells, the MEK inhibitor decreased …
Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of Cancer
C Salva de Torres, I Baraibar… - International Journal of …, 2024 - mdpi.com
39 天前 - … -mutated CRC setting. Moreover, studies in preclinical models have shown that
combined BRAF and MEK inhibition … , KRAS G12C inhibitors, and BRAF and MEK inhibitors, as …
combined BRAF and MEK inhibition … , KRAS G12C inhibitors, and BRAF and MEK inhibitors, as …
[引用][C] MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a Young Adult Patient: A Case Report
44 天前 - MEK Inhibition in a Pilocytic Astrocytoma With a Rare KRAS Q61R Mutation in a
Young Adult Patient: A Case Report | JCO Precision Oncology …
Young Adult Patient: A Case Report | JCO Precision Oncology …
Intermittent MEK inhibition with GITR co-stimulation rescues T-cell function for increased efficacy with CTLA-4 blockade in solid tumor models
47 天前 - … -stimulation via GITR and OX-40 agonist antibodies completely alleviated inhibition
of function. In Kras mutant lung and colon tumor mouse models, intermittent CKI27 and anti-…
of function. In Kras mutant lung and colon tumor mouse models, intermittent CKI27 and anti-…
MEK inhibitors and DA‐Raf, a dominant‐negative antagonist of the Ras–ERK pathway, prevent the migration and invasion of KRAS‐mutant cancer cells
A Matsuda, R Masuzawa, K Takahashi, K Takano… - …, 2024 - Wiley Online Library
51 天前 - … that targets mutant Ras protein-induced tumorigenesis. We show here that MEK
inhibitors and … cell migration and invasion of human KRAS-mutant carcinoma cell lines, the lung …
inhibitors and … cell migration and invasion of human KRAS-mutant carcinoma cell lines, the lung …
BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer
S Tokuyama, H Kato, H Takahashi, K Ueda… - …, 2024 - academic.oup.com
52 天前 - … of oncogenes, such as KRAS or BRAF mutations. It has been … synergistic effect of
p53 activation and MEK inhibition in … MEK inhibition and p53 activation had synergistic effects. …
p53 activation and MEK inhibition in … MEK inhibition and p53 activation had synergistic effects. …
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination
R Rosell, E Jantus-Lewintre, P Cao, X Cai… - Cell Communication and …, 2024 - Springer
53 天前 - … proton pump inhibitor with … MET inhibitor tepotinib in KRAS-mutant G12C and
non-G12C NSCLC cell lines, as well as in G12C inhibitor (AMG510, sotorasib) and MEK inhibitor (…
non-G12C NSCLC cell lines, as well as in G12C inhibitor (AMG510, sotorasib) and MEK inhibitor (…
相关搜索
- small cell lung cancer kras mutations
- dual mek inhibitor ras mutant tumors
- kras mutant inhibitor trametinib
- mek inhibition braf mutant colorectal cancer
- pulsatile mek inhibition
- mek inhibitor resistance
- mek inhibition gitr co-stimulation
- mek inhibition systemic immunomodulatory effects
- mek inhibitor selumetinib
- proliferation and survival signals kras mutations
- dual mek inhibitor ctla4 checkpoint blockade
- negative antagonist kras mutant cancer cells
- mek inhibition pilocytic astrocytoma
- mek inhibition solid tumor models
- mek inhibition ctla 4 blockade
- mek inhibition increased efficacy